Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

Glioblastoma Clinical Trial

Official title:

Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01364064
• Other study ID #: RAC#2081-018
• Status: Completed
• Phase: Phase 3
• First received: May 31, 2011
• Last updated: February 24, 2016
• Start date: January 2007
• Est. completion date: June 2008

Study information

• Verified date: September 2013
• Source: King Faisal Specialist Hospital & Research Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This is a Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma.

Description:

Primary objective is to determine if dose-intensifying (increasing the "dose-density") the adjuvant temozolomide component of the chemoradiation treatment enhances treatment efficacy as measured by overall survival.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1153
• Est. completion date: June 2008
• Est. primary completion date: June 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Karnofsky performance status of = 60. 2. Age = 18 years. 4. CBC/differential obtained within 14 days prior to study registration, with adequate bone marrow function as defined below:

• Absolute neutrophil count (ANC) = 1500 cells/mm3.

• Platelets = 100,000 cells/mm3.

• Hemoglobin = 10 g/dl. (Note: The use of transfusion or other intervention to achieve Hgb = 10 g/dl is acceptable.)

• Adequate renal function, as defined below:

• BUN = 25 mg/dl within 14 days prior to study registration

• Creatinine = 1.7 mg/dl within 14 days prior to study registration 4. Adequate hepatic function, as defined below:

• Bilirubin = 2.0 mg/dl within 14 days prior to study registration

• ALT = 3 x normal range within 14 days prior to study registration

• AST = 3 x normal range within 14 days prior to study registration 5. Patients must sign a study-specific informed consent prior to study registration.

If the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the responsible family member.

6. For females of child-bearing potential, negative serum pregnancy test within 72 hours prior to starting temozolomide.

7. Women of childbearing potential and male participants must practice adequate contraception.

Exclusion Criteria:

1. Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for = 3 years. (For example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible).

2. Recurrent or multifocal malignant gliomas

3. Metastases detected below the tentorium or beyond the cranial vault.

4. Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable. Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted.

5. Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields.

6. Severe, active co-morbidity, defined as follows:

• Unstable angina and/or congestive heart failure requiring hospitalization

• Transmural myocardial infarction within the last 6 months

• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

• Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

• Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.

• Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.

• Major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.

• Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Drug:
• TMZ
Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
King Faisal Specialist Hospital & Research Center	Radiation Therapy Oncology Group

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety and efficacy		5 years	No